ClinicalTrials.gg
RecruitingNCT07558850Updated Apr 30, 2026

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

An interventional study of anti-CD19/BCMA-UCAR-T cells in Rheumatoid Arthritis, Dermatomyositis and Systemic Lupus Erythematosus, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
138th of 217
72 · median 134
Started
2026
with 18 others
No phase
45 of 249
15 open now
Primary completion
2028-01
later than 56 of 71 live
Registered
241st of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 138th largest by planned enrollment of the 217 interventional ones that give a count, is one of 19 that started in 2026, is one of 45 with no phase, reaches primary completion later than 56 of the 71 other live ones, and was the 241st registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA-UCAR-T cells in patients with autoimmune diseases.

36-72 patients are planned to be enrolled in the dose-escalation trial.

03

Conditions studied

  • Rheumatoid Arthritis
  • Dermatomyositis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Common Inclusion Criteria

    1. Voluntarily sign an form, understand the study, and be willing and capable of completing all trial procedures.
    2. Aged 18 to 70 years, regardless of gender.
    3. At screening, the number of peripheral blood CD19-positive B cells determined by flow cytometry > 5 cells/μL.
    4. For subjects previously treated with B-cell targeted therapy, peripheral blood B cell counts have returned to normal or above pre-treatment levels at the screening visit.
    5. Complete blood counts within 7 days prior to lymphodepleting chemotherapy meet the following requirements in patients with Sjögren's disease (SjD):

      (ANC) ≥ 1.5×10⁹/L (Hb) ≥ 80 g/L count (PLT) ≥ 50×10⁹/L

    6. Subjects have adequate hepatic, renal, pulmonary and cardiac function at screening visit, defined as:

      (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × (ULN) Total (TBIL) ≤ 1.5 × ULN; except for patients with Gilbert syndrome, whose TBIL must be ≤ 3.0 × ULN Renal function: estimated (eGFR) ≥ 30 mL/min/1.73m². Subjects with eGFR \< 30 mL/min/1.73m² and/or receiving renal replacement therapy may be enrolled if the investigator assesses benefits outweigh risks and full informed consent is obtained from the subject or guardian.

      Peripheral oxygen saturation (SpO₂) ≥ 92% under room air without oxygen supplementation; no pleural effusion (excluding that related to the target indication).

      (LVEF) ≥ 50%; no pericardial effusion confirmed by echocardiography (excluding indication-related effusion); no clinically significant abnormalities on (ECG).

    7. During the screening period, serum pregnancy test must be negative for fertile female subjects. Females who have undergone surgical sterilization or natural menopause for at least 2 years are considered non-fertile. Fertile female and male subjects must adopt highly effective methods throughout the clinical study and for 1 year after the last study treatment. They shall also agree not to donate oocytes or sperm for assisted reproductive technology within 1 year following the final study treatment.

      Specific Inclusion Criteria

      Rheumatoid Arthritis (RA)

    8. Meet the 2010 ACR/EULAR classification diagnostic criteria, diagnosed with moderate to severe active rheumatoid arthritis, with a confirmed RA diagnosis for ≥ 6 months.
    9. Swollen joint count ≥ 6 (based on 66-joint assessment) and tender joint count ≥ 6 (based on 68-joint assessment) at screening.
    10. C-reactive protein (CRP) ≥ 10 mg/L or erythrocyte sedimentation rate (ESR) ≥ 28 mm/h at screening.
    11. Definition of EULAR refractory rheumatoid arthritis:

      Treatment failure: Patients received treatment in accordance with EULAR recommended guidelines, and failed to respond to ≥ 2 biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following failure of conventional synthetic DMARDs (csDMARDs).

      ① Exclusions: Treatment access restricted to bDMARDs/tsDMARDs due to socioeconomic factors.

      ② If csDMARDs are , treatment failure with ≥ 2 b/tsDMARDs with distinct mechanisms of action also qualifies.

      Both patients and physicians acknowledge persistent difficulties in managing RA symptoms.

      Presence of at least one of the following five indicators suggestive of active or progressive disease:

      1. Moderate or higher disease activity (DAS28-ESR > 3.2 or CDAI > 10);
      2. Clinical signs and/or symptoms indicative of active disease;
      3. Inability to taper to ≤ 7.5 mg/day prednisone or equivalent dose;
      4. Rapid radiographic progression (increase in modified van der Heijde Sharp score ≥ 5 points within 1 year);
      5. Impaired quality of life secondary to RA, despite seemingly adequate disease control.

      Dermatomyositis (DM)

    12. Diagnosed with Dermatomyositis (DM) in accordance with the 2017 EULAR/ACR criteria for at least 24 weeks prior to informed consent (ICF) signing.
    13. Meet the classification criteria for refractory DM, and satisfy criterion ① plus any one of criteria ②-⑤:① Insufficient response to glucocorticoids (prednisone 1-2 mg/kg/day or equivalent dose of other corticosteroids) combined or sequential treatment with at least two , with glucocorticoid treatment lasting for no less than 3 months;② Rapid disease progression, and/or involvement of extrapulmonary organs including the heart and gastrointestinal tract, and/or significant interstitial lung disease;③ Calcification in subcutaneous, muscular and articular tissues;④ Recurrent rashes or cutaneous ulcers;⑤ Recurrent or persistent muscle weakness. MRI shows extensive diffuse muscle edema during the disease course, or CMAS score \< 48. At least two abnormal results among the five core parameters: Physician Global Assessment (PhGA) ≥ 2 cm, Patient Global Assessment (PtGA) ≥ 2 cm, Manual Muscle Test MDAAT ≥ 2, Health Assessment Questionnaire (HAQ) total score ≥ 0.25, muscle enzyme levels > 1.5 × upper limit of normal (ULN).
    14. Patients with anti-synthetase syndrome and positive anti-synthetase antibodies meet DM criteria and may be enrolled directly.
    15. Patients with immune-mediated necrotizing myopathy positive for SRP or HMGCR antibodies meet DM criteria and may be enrolled directly.

      Systemic Lupus Erythematosus (SLE)

    16. Diagnosed with adult systemic lupus erythematosus (SLE) in accordance with the 2019 EULAR/ACR SLE classification criteria for at least 12 weeks prior to signing the informed consent form (ICF).
    17. Subjects with moderate to severe refractory SLE shall meet all of the following criteria:

      Positive antinuclear antibody (ANA) with a titer >1:80 at screening visit; or anti-double stranded DNA antibody level above the laboratory normal reference range (excluding borderline values); or anti-Sm antibody level above the laboratory normal reference range.

      BILAG score showing Grade A involvement in ≥1 organ system, or Grade B involvement in ≥2 organ systems at both screening and baseline visits.

      SLEDAI-2000 score ≥ 8 at both screening and baseline visits. Insufficient clinical response following adequate standard-dose glucocorticoids, antimalarials, immunosuppressants, and at least one biological agent administered in combination or sequentially for ≥ 3 months prior to screening.

    18. Subjects receiving hematopoietic growth factor supportive therapy, including erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and thrombopoietin (TPO), must have an interval of at least 2 weeks between the last dose of growth factor therapy and screening assessments.For subjects receiving blood product transfusions: platelet assessments at screening shall be separated by at least 1 week from the last platelet transfusion; hemoglobin assessments at screening shall be separated by at least 2 weeks from the last red blood cell transfusion.

      Systemic Sclerosis (SSc)

    19. Meet the 2013 ACR/EULAR classification criteria for systemic sclerosis, with disease duration ≤ 60 months.
    20. Positive for antinuclear antibody (ANA) or any SSc-specific autoantibody.
    21. Modified Rodnan Skin Score (mRSS) ≥ 15 (full score: 51).
    22. Meet the definition of refractory disease:

      • Significant progressive involvement of skin and visceral organs; ② No obvious disease remission after more than 3 months of combined or sequential treatment with glucocorticoids and/or cyclophosphamide, plus one or more immunomodulatory agents including but not limited to antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, ciclosporin, and biological agents such as rituximab, belimumab, telitacicept.Alternatively, subjects meeting criteria for rapidly progressive disease with no response to conventional standard clinical therapy may be enrolled if the investigator determines that clinical benefits outweigh risks and full informed consent is obtained from the subject or legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Common Exclusion Criteria

    1. History of malignant tumors (excluding cured and completely resected basal cell carcinoma, squamous cell skin carcinoma or cervical carcinoma in situ with a disease-free interval of at least 5 years post resection), or concurrent malignant tumors.
    2. Complicated severe pulmonary diseases, including pulmonary hypertension graded ≥ Grade 3 per WHO functional classification, requirement for oxygen therapy via oxygen reservoir mask, non-invasive or invasive mechanical ventilation support at screening.
    3. Known allergy, , intolerance or to CD19/BCMA CAR-NK cells or any medicinal ingredients (including fludarabine, cyclophosphamide and tocilizumab), or history of severe anaphylactic reactions.
    4. Evidence of severe active viral, bacterial infection or uncontrolled systemic fungal infection at screening or baseline visit.
    5. Cardiac insufficiency classified as Class Ⅲ or Ⅳ according to New York Heart Association criteria (see Appendix).
    6. Congenital heart disease prior to screening, history of acute myocardial infarction within 6 months, severe arrhythmia (including multifocal frequent supraventricular tachycardia, ventricular tachycardia, etc.), moderate to massive pericardial effusion, severe myocarditis; unstable vital signs requiring vasopressor support.
    7. Active or uncontrolled infection requiring parenteral antimicrobial therapy at screening or baseline visit.
    8. Positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral HBV DNA level above ; positive antibody with peripheral HCV RNA level above upper limit of normal; positive antibody, positive syphilis serology, or positive cytomegalovirus (CMV) DNA.
    9. History of severe herpes infection such as herpes encephalitis, ocular herpes or disseminated herpes; signs of herpes or varicella-zoster virus infection (particularly varicella and herpes zoster) within 12 weeks prior to screening.
    10. Active tuberculosis, history of active tuberculosis, or negative interferon-gamma release assay for tuberculosis infection not achieved during screening period.
    11. History of epilepsy or other active central nervous system disorders.
    12. Subjects with acquired or congenital immunodeficiency diseases.
    13. Any cardiac, endocrine, hematological, hepatic, immune, metabolic, urinary, pulmonary, neurological, dermatological, psychiatric, renal disorders or major medical history that may interfere with KN3601 administration, as judged by the investigator.
    14. Solid organ transplantation or hematopoietic stem cell transplantation within 3 months prior to screening; acute (GVHD) Grade ≥2 within 2 weeks prior to screening.
    15. Administration of within 4 weeks prior to screening.
    16. Receipt of the following treatments within specified time windows before baseline visit:

      B-cell depleting therapy within 26 weeks Anti-0 monoclonal antibody, belimumab, abatacept, anti-tumor necrosis factor-α biologics, immunoglobulin therapy or plasma exchange within 24 weeks JAK inhibitors or other kinase inhibitors within 12 weeks, unless explicitly permitted by the protocol Traditional Chinese medicines and proprietary Chinese medicines for Sjögren's disease within 4 weeks (including Tripterygium wilfordii, Tripterygium hypoglaucum, Tripterygium hypoglaucum root, Paeonia lactiflora, and preparations/supplements containing the above ingredients) Prior treatments within 3 elimination half-lives, 4 weeks, or ongoing pharmacodynamic effect, whichever is longer Post prior B-cell depleting therapy with B lymphocyte count below lower limit of normal or baseline value, whichever is lower

    17. Participation in other clinical trials within 3 months, excluding subjects confirmed not to receive investigational drugs or devices.
    18. Any conditions that, in the investigator's opinion, may elevate subject risk or confound trial outcomes.

      Specific Exclusion Criteria Rheumatoid Arthritis (RA)

    19. ACR functional class Grade 4 for rheumatoid arthritis. Dermatomyositis (DM)
    20. Paraneoplastic myositis, defined as myositis diagnosed within 2 years following cancer diagnosis, or subjects categorized as high-risk for .
    21. Subjects with overlap syndrome (excluding overlap with Sjögren's syndrome), connective tissue disease-associated DM other than primary DM, inclusion body myositis, polymyositis, or drug-induced myopathy.
    22. Subjects with severe systemic musculoskeletal disorders other than DM, which interfere with adequate investigator assessment of disease activity.

      Systemic Lupus Erythematosus (SLE)

    23. Renal pathological diagnosis of Class V lupus nephritis (excluding Class III or IV lupus nephritis complicated with Class V lupus nephritis); active nephritis requiring treatment with protocol-prohibited medications, or requirement for hemodialysis.

      Systemic Sclerosis (SSc)

    24. Concurrent rheumatic diseases other than SSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, polymyositis and dermatomyositis, as determined by the investigator.Note: Subjects with fibromyalgia, secondary Sjögren's syndrome, and scleroderma-associated myopathy at screening will not be excluded.
    25. Non-SSc cutaneous lesions that impair accurate investigator evaluation of disease activity.
    26. History of scleroderma renal crisis occurring within 2 years prior to screening visit.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    KN3601

    Biological: anti-CD19/BCMA-UCAR-T cells

Interventions

  • Biologicalanti-CD19/BCMA-UCAR-T cells

    Patients will receive Fludarabine and Cyclophosphamide on day-5, -4, and -3. Single dose of anti-CD19/BCMA CAR T cells (KN3601) will infused using dose-escalation strategy.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (DLT)

    To characterize the safety of anti-CD19/BCMA-UCAR T Cells (KN3601) for patients with Relapsed/Refractory autoimmune diseases

    Time frame: up to 48 weeks after infusion

  2. Incidence of Treatment Emergent Adverse Events (TEAEs)

    To characterize the safety of anti-CD19/BCMA U CAR T Cells (KN3601) for patients with Relapsed/Refractory autoimmune diseases

    Time frame: up to 48 weeks after infusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jan 2028, 20 months later.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 20 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
Apr 30, 2026
StartEst.
May 10, 2026
Primary completionEst.
Jan 10, 2028
CompletionEst.
Jan 10, 2029
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07558850
Collaborators
Rui Therapeutics Co., Ltd
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
May 10, 2026 (estimated)
Primary completion
Jan 10, 2028 (estimated)
Completion
Jan 10, 2029 (estimated)
Last update
Apr 30, 2026

Study contacts

Wenfeng Tan
Contact
Tanwenfeng2005@126.com
13770769608

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion